Os therapies incorporated OSTX.US Overview
OSTX AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
OSTX Current Performance
-5.46%
Os therapies incorporated
-1.01%
Avg of Sector
-0.79%
S&P500
OSTX Key Information
OSTX Financial Forecast
Unit : USD
OSTX Earnings Table
OSTX Profile
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Price of OSTX
OSTX FAQ
When is OSTX's latest earnings report released?
The most recent financial report for Os therapies incorporated (OSTX) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OSTX’s short-term business performance and financial health. For the latest updates on OSTX’s earnings releases, visit this page regularly.
How much cash does OSTX have?
At the end of the period, Os therapies incorporated (OSTX) held Total Cash and Cash Equivalents of 2.97M, accounting for 0.7 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is OSTX's EPS continuing to grow?
According to the past four quarterly reports, Os therapies incorporated (OSTX)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.18. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of OSTX?
Os therapies incorporated (OSTX)’s Free Cash Flow (FCF) for the period is -3.44M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 436.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.